Daniel Stover, Associate Professor of Medicine and the Director of Translational Breast Cancer Research at the Ohio State University Comprehensive Cancer Center, shared a post on LinkedIn:
“In breast cancer,
-We have focused on germline alterations/variation and predicted risk of developing breast cancer as well as therapeutic response.
-We have also focused on somatic tumor genomic alterations and how these can match patients to specific therapies.
We have not focused enough on the interplay of germline-somatic features. I love that the field is addressing that gap!
Fantastic work from Pedram Razavi Sarat Chandarlapaty and team out in Nature Magazine.”
Title: Homologous recombination deficiency and hemizygosity drive resistance in breast cancer
Authors: Anton Safonov, Minna Lee, David N. Brown, Luca Boscolo Bielo, Miika Mehine, Chaitanya Bandlamudi, Ben O’Leary, Hong Shao, Laia Vicente, Daniel Muldoon, Allen Zhu, Susana Ros, Antonio Marra, Pier Selenica, Ivan Bieche, Bradley Wubbenhorst, Emanuela Ferraro, Laura Courtois, Rania El Botty, Mehnaj Ahmed, Enrico Moiso, Julia Ah-Reum An, Mark T. A. Donoghue, Marie Will, Fresia Pareja, Emily Nizialek, Natalia Lukashchuk, Eleni Sofianopoulou, Yuan Liu, Xin Huang, Colombe Chappey, Anna D. Staniszewska, Dara Ross, Diana Mandelker, Marc Ladanyi, Nikolaus Schultz, Michael F. Berger, Maurizio Scaltriti, Jorge S. Reis-Filho, Bob T. Li, Kenneth Offit, Larry Norton, Ronglai Shen, Kara N. Maxwell, Fergus Couch, Susan M. Domchek, Elisabetta Marangoni, Sohrab Shah, Mark R. Albertella, Violeta Serra, Britta Weigelt, David B. Solit, Katherine L. Nathanson, Mark E. Robson, Nicholas C. Turner, Sarat Chandarlapaty, Pedram Razavi
Other articles featuring Daniel Stover on OncoDaily.